Company: PRTA
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001559053-25-000023
Chunk: 44

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 2
Chunk 44
---
2025                  2026      2027      2028  
  Operating leases (1)                                  $          11,332      $          2,382      $         $         $     
  Purchase obligations (2)                                         15,554                15,439      115       —         —     
  Contractual obligations under license agreements      319                    69                    70        70        55    
  Total                                                 $          27,205      $         17,890      $         $         $     

(1)See Note 6,“ Commitments and Contingencies” to our Condensed Consolidated Financial Statements.

(2) As of the filing date, there were no material changes to our Purchase obligations subsequent to March 31, 2025.

In addition to the contractual obligations above, we also expect to have future material cash requirements related to our clinical trials, discovery and pre-clinical programs, human capital and intellectual property. Assuming no significant change in our business, we expect the full year 2025 net cash used in operating and investing activities to be approximately $168 million to $175 million.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK